KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gains from Investment Securities (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 16 years of Gains from Investment Securities data on record, last reported at -$148.4 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 81.72% year-over-year to -$148.4 million; the TTM value through Dec 2025 reached -$135.5 million, down 275.35%, while the annual FY2025 figure was -$135.5 million, 275.35% down from the prior year.
  • Gains from Investment Securities reached -$148.4 million in Q4 2025 per REGN's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.2 billion in Q4 2022 and bottomed at -$811.8 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $76.6 million, with a median of -$100000.0 recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 7723.26% in 2024, then tumbled 3100.0% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$28.7 million in 2021, then skyrocketed by 4440.77% to $1.2 billion in 2022, then crashed by 119.46% to -$242.4 million in 2023, then crashed by 234.9% to -$811.8 million in 2024, then surged by 81.72% to -$148.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$148.4 million in Q4 2025, $3.0 million in Q3 2025, and $13.1 million in Q2 2025.